The European Organisation for Research and Treatment of Cancer (EORTC), and the American Association for Cancer Research (AACR) and the National Cancer Institute (NCI) in the USA are joining forces for the Symposium, where the latest advances in pre-clinical and clinical research will be presented.

Building on the success and focus of previous highly acclaimed symposiums, this drug development and translational research meeting, focusing on preclinical and phase I studies, will enable delegates to have in-depth scientific discussions on the latest developments in targets and drugs.

Around 1,500 international experts will be discussing innovations in drug development, target selection and the impact of new discoveries in molecular biology.